Oppenheimer analyst Justin Kim maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) on Wednesday, setting a price target of $22, which is approximately 40.85% above the present share price of $15.62.
Kim expects Aurinia Pharmaceuticals to post earnings per share (EPS) of $0.00 for the second quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Aurinia Pharmaceuticals, with an average price target of $25.4.
The analysts price targets range from a high of $32 to a low of $20.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $30 thousand and a net profit of -$25.27 million. The company's market cap is $1.71 billion.
According to TipRanks.com, Oppenheimer analyst Justin Kim is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 41.2% and a 62.50% success rate.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.